Cargando…
Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study
Ozanimod is a novel, selective, oral sphingosine‐1‐phosphate (1 and 5) receptor modulator in development for multiple sclerosis and inflammatory bowel disease. This randomized, double‐blind, placebo‐controlled, positive‐controlled, parallel‐group thorough QT study characterized the effects of ozanim...
Autores principales: | Tran, Jonathan Q., Hartung, Jeffrey P., Olson, Allan D., Mendzelevski, Boaz, Timony, Gregg A., Boehm, Marcus F., Peach, Robert J., Gujrathi, Sheila, Frohna, Paul A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901414/ https://www.ncbi.nlm.nih.gov/pubmed/28783871 http://dx.doi.org/10.1002/cpdd.383 |
Ejemplares similares
-
Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator
por: Tran, Jonathan Q., et al.
Publicado: (2017) -
Effects of High‐ and Low‐Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator
por: Tran, Jonathan Q., et al.
Publicado: (2017) -
No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects
por: Demmel, Valentin, et al.
Publicado: (2018) -
“Thorough QT/QTc in a Dish”: Can Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Predict Thorough QT Outcomes?
por: Vargas, Hugo M.
Publicado: (2019) -
Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS
por: Harris, Sarah, et al.
Publicado: (2020)